Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: rituximab

COPA Syndrome: What Do We Know About This Rare Disease?

Lara C. Pullen, PhD  |  April 17, 2021

ACR CONVERGENCE 2020—Tiphanie Phillips Vogel, MD, PhD, assistant professor of pediatrics and internal medicine at Baylor College of Medicine, Houston, moderated the session on COPA syndrome, which drew 324 attendees on a Sunday morning. This rare genetic cause of immune dysregulation can present like anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, lupus, lupus nephritis or rheumatoid…

Filed under:Conditions Tagged with:ACR Convergence 2020COPAgenetic diseasemimics

14 Rheumatology Treatments Make Top 50 List of Drugs That Can Cause Anaphylaxis

Michele B. Kaufman, PharmD, BCGP  |  April 15, 2021

A recent study of data from the FDA’s Adverse Event Reporting System reveals that 14 drugs commonly prescribed by rheumatologists are on the list of the top 50 drugs that can cause anaphylaxis.

Filed under:Drug Updates Tagged with:anaphylaxisFDAMedwatchU.S. Food and Drug Administration (FDA)

COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy

Marilynn Larkin  |  March 29, 2021

NEW YORK (Reuters Health)—U.K. experts propose evidence-based management strategies for rheumatology patients on immunosuppressive therapy, including delaying/postponing rituximab, as appropriate. “The aim of this viewpoint article is to outline the existing data on the effect of anti-rheumatic therapy on vaccine responses in patients with inflammatory arthritis and to formulate a possible pragmatic strategy for the…

Filed under:Conditions Tagged with:COVID-19immunosuppressive therapyrituximabU.K.vaccination

When Switching Patients to Biosimilars, Communication & Expert Nurses Reduce the Nocebo Effect

Lara C. Pullen, PhD  |  March 22, 2021

In a recent study, researchers designed an intervention centered on communication and led by nurses to address discontinuation rates among patients who had switched to a biosimilar. The nurses’ insight and experience reduced the nocebo effect during the intervention, which had an 84% retention rate for patients taking a biosimilar after one year.

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biologics & Biosimilarsinfliximabinfliximab-abdanon-medical switchingRenflexis (infliximab-abda)

Prostock-studio / shutterstock.com

Case Report: Evans Syndrome in Lupus

Matthew J. Herrmann, MD, & Faizah Siddique, MD  |  March 15, 2021

Rheumatologists are in the unique position of diagnosing and treating rare auto-inflammatory and autoimmune diseases. Although systemic lupus erythematosus (SLE) often has textbook presentations, it is a heterogeneous condition with a wide variety of disease manifestations.  In 2019, the European League Against Rheumatism and the ACR introduced new classification criteria to help diagnose this condition.1…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:case reportEvans Syndrome

Neti Pots, Nurse Ambassadors & American Healthcare

Philip Seo, MD, MHS  |  March 15, 2021

Just YouTube it. As a rheumatologist who sees many patients with granulomatosis with polyangiitis (GPA), I have spent a significant portion of my life talking to people about neti pots. Originally, the neti pot was part of the Ayurvedic tradition. Neti pots were used to flush the sinuses with water, milk and ghee, or to…

Filed under:OpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:medication compliancenurse ambassadors

Case Report: Drug-Induced Lupus & ANCA-Associated Vasculitis Overlap

Mohammad A. Ursani, MD, RhMSUS, Ojas Naik, MD, Rohaan Khan & William F. Glass II, MD, PhD  |  February 16, 2021

Drug-induced lupus erythe­matosus and ANCA-associated vasculitis (AAV) are both autoimmune conditions associated with the use of hydralazine, a commonly prescribed drug for hypertension and congestive heart failure. Although the pathogenesis is unknown, it is believed that hydralazine alters neutrophil and lymphocyte function and promotes exposure of antigens, leading to the development of anti-neutrophil antibodies (ANCA)…

Filed under:ConditionsSystemic Lupus ErythematosusVasculitis Tagged with:ANCA-Associated Vasculitiscase reporthydralazine

B Cell Depletion: The Latest Information on Disease Processes, Therapies

Lara C. Pullen, PhD  |  January 25, 2021

Experts discussed the latest knowledge on B cell disease processes, and what it might mean for future B cell depletion therapies.

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2020B cell depletionB cells

Case Report: A Non-Tuberculous Mycobacterial Infection

Bradley Bohman, MD, & Jawad Bilal, MBBS  |  January 20, 2021

Tumor necrosis factor-α inhibitors (TNFi’s) have emerged as an integral part of therapeutic strategies for several rheumatic diseases. TNF-α is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis (RA), seronegative spondyloarthropathies and inflammatory bowel disease (IBD). It also plays a central role in the immune response to mycobacterial infection.  Many biologic agents, particularly…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:bacteriacase reportInfectiontumor necrosis factor inhibitor (TNFi)

ilusmedical / shutterstock.com

The State of Clinical Research in Vasculitis: 2021

Shubhasree Banerjee, MD, & Peter A. Merkel, MD, MPH  |  January 19, 2021

It is an exciting time in the world of vasculitis research. More clinical studies and trials are being conducted now than at any time in history. In the past ten years, four drugs have been approved by the U.S. Food & Drug Administration (FDA) and other regulatory agencies specifically for the treatment of vasculitis: Rituximab…

Filed under:ConditionsResearch RheumVasculitis Tagged with:registry

  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 45
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences